Antibiotic Resistant Sepsis Pathogens
Antimicrobial resistance is a severe threat globally. Infectious diseases claim more lives each year and are second only to heart diseases. Antibiotic intervention is one the most powerful and cost-effective medical actions, but is under severe threat from antibiotic resistance both in Australia and globally. Although antimicrobial resistance occurs naturally, inappropriate use in the community has led to high levels of resistance.
Studies tracking the spread of antimicrobial resistant pathogens suggests that the co-evolution of increased bacterial virulence may play a role in the spread of resistant bacterial strains. This relationship is currently not well understood. A better understanding of bacterial infection and virulence (for example through established bloodstream infections or sepsis) is crucial to the development of new approaches to clinical management. Ideally, these approaches would minimise the impact of the bacterial infection but does not subsequently increase the bacteria's ability to resist antimicrobial treatments.
This strategy requires the coordinated action of multi-disciplinary teams to identify common pathogenic pathways that may be exploited for the early diagnosis, treatment and prevention of life-threatening bacterial infections. This was undertaken using a consortium-based approach. Data analysis and integration are on-going efforts.
For more information, please visit: http://www.bioplatforms.com/antibiotic-resistant-pathogens/
The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.
The pathogens included in this Initiative are:
Strains will be grown in defined laboratory media and in pooled human sera (to mimic sepsis conditions).
The outcomes of the studies will allow researchers to:
1) Compare RNA, metabolite and protein expression of the same strain in two different growth conditions
2) Compare RNA, metabolite and protein expression among strains of the same species
Experimental setup, methods and data access
- Strain selection | Bacterial Contextual Data
- Experimental setup | Methods | Training material (bioinformatics)
- Data Access | Data Management (Consortium members only)
- Project Contacts
- Consortium Members
- Conference presentations
- Data Release Policy
- Strain Access Policy
- Open Science Framework page (Consortium members only)
Invitation to Collaborate
Bioplatforms Australia promotes data sharing and collaborative interactions are encouraged to advance scientific discovery and maximize the value to the community from this Australian Government (NCRIS)-funded dataset. As such, the consortium would like to extend an invitation to collaborate.
Data from the Initiative is made available to members of the consortium upon generation. Following a period of mediated access, where access to the data will be limited to members of the consortium and other approved parties, the data will be made available publicly.
Should you wish to access the data during this mediated period, please email (firstname.lastname@example.org) with your name, affiliation, specific data for which access is being requested and a brief outline of the intended data use. This information will be assessed by Bioplatforms Australia and the consortium, and you will be contacted to discuss collaborative access.
Please find the Data Release Policy here (https://data.bioplatforms.com/organization/pages/bpa-sepsis/data-release-policy).
Acknowledging the consortium
When using Antibiotic Resistant Sepsis Pathogens Framework Initiative data, please acknowledge the Consortium and Bioplatforms Australia support using the following wording:
"We would like to acknowledge the contribution of the Antibiotic Resistant Sepsis Pathogens Framework Initiative consortium (https://data.bioplatforms.com/organization/pages/bpa-sepsis/consortium) in the generation of data used in this publication. The Initiative is supported by funding from Bioplatforms Australia through the Australian Government National Collaborative Research Infrastructure Strategy (NCRIS)."